Geron Corporation (GERN)
USD 1.3
(-6.16%)
USD 1.3
(-6.16%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -174.78 Million USD | -42.88% |
| 2022 | -134.15 Million USD | -21.0% |
| 2021 | -111.58 Million USD | -48.95% |
| 2020 | -73.92 Million USD | -3.33% |
| 2019 | -67.77 Million USD | -122.87% |
| 2018 | -26.95 Million USD | -16.86% |
| 2017 | -29.17 Million USD | 5.48% |
| 2016 | -30.56 Million USD | -2168.4% |
| 2015 | 803 Thousand USD | 103.96% |
| 2014 | -35.62 Million USD | 0.79% |
| 2013 | -38.05 Million USD | 45.08% |
| 2012 | -67.81 Million USD | 20.16% |
| 2011 | -95.03 Million USD | -99.77% |
| 2010 | -109.67 Million USD | 41.25% |
| 2009 | -68.28 Million USD | -8.23% |
| 2008 | -59.91 Million USD | 14.83% |
| 2007 | -62.83 Million USD | -43.56% |
| 2006 | -47.36 Million USD | -33.53% |
| 2005 | -35.84 Million USD | -408.32% |
| 2004 | -32.23 Million USD | 151.11% |
| 2003 | -26.05 Million USD | 18.74% |
| 2002 | -31.11 Million USD | -66.02% |
| 2001 | -30.64 Million USD | 13.08% |
| 2000 | -21.55 Million USD | -442.21% |
| 1999 | -17.1 Million USD | 146.32% |
| 1998 | -10.9 Million USD | -22.52% |
| 1997 | -9.3 Million USD | 13.28% |
| 1996 | -11 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -55.85 Million USD | -4.59% |
| 2024 Q2 | -68.9 Million USD | -23.13% |
| 2023 Q3 | -47.61 Million USD | -1.41% |
| 2023 FY | - USD | -42.88% |
| 2023 Q2 | -46.94 Million USD | -29.69% |
| 2023 Q4 | -54.04 Million USD | -13.52% |
| 2023 Q1 | -36.2 Million USD | 10.9% |
| 2022 Q1 | -28.42 Million USD | 7.29% |
| 2022 FY | - USD | -21.0% |
| 2022 Q4 | -40.63 Million USD | -3.56% |
| 2022 Q3 | -39.23 Million USD | -49.07% |
| 2022 Q2 | -26.32 Million USD | 7.39% |
| 2021 Q2 | -28.58 Million USD | -6.25% |
| 2021 Q3 | -25.44 Million USD | 10.96% |
| 2021 Q4 | -30.65 Million USD | -20.46% |
| 2021 Q1 | -26.9 Million USD | -17.04% |
| 2021 FY | - USD | -48.95% |
| 2020 Q4 | -22.98 Million USD | -18.5% |
| 2020 Q2 | -16.39 Million USD | 1.69% |
| 2020 Q1 | -16.67 Million USD | 44.43% |
| 2020 FY | - USD | -3.33% |
| 2020 Q3 | -19.39 Million USD | -18.31% |
| 2019 Q4 | -30 Million USD | -87.98% |
| 2019 Q3 | -15.96 Million USD | -4.93% |
| 2019 FY | - USD | -122.87% |
| 2019 Q2 | -15.21 Million USD | -34.8% |
| 2019 Q1 | -11.28 Million USD | -2.14% |
| 2018 Q1 | -7.15 Million USD | 3.49% |
| 2018 Q3 | -6.79 Million USD | 6.03% |
| 2018 FY | - USD | -16.86% |
| 2018 Q4 | -11.04 Million USD | -62.7% |
| 2018 Q2 | -7.22 Million USD | -1.05% |
| 2017 Q1 | -7.14 Million USD | 15.58% |
| 2017 FY | - USD | 5.48% |
| 2017 Q4 | -7.41 Million USD | -8.0% |
| 2017 Q3 | -6.86 Million USD | -7.77% |
| 2017 Q2 | -6.36 Million USD | 10.85% |
| 2016 FY | - USD | -2168.4% |
| 2016 Q3 | -3.53 Million USD | 58.89% |
| 2016 Q1 | -8.8 Million USD | -4.17% |
| 2016 Q2 | -8.59 Million USD | 2.31% |
| 2016 Q4 | -8.46 Million USD | -139.39% |
| 2015 FY | - USD | 103.96% |
| 2015 Q2 | -8.38 Million USD | 5.85% |
| 2015 Q4 | -8.44 Million USD | -131.08% |
| 2015 Q3 | 27.18 Million USD | 424.38% |
| 2015 Q1 | -8.9 Million USD | 0.11% |
| 2014 Q3 | -9.81 Million USD | -14.81% |
| 2014 Q4 | -8.91 Million USD | 9.22% |
| 2014 FY | - USD | 0.79% |
| 2014 Q1 | -8.63 Million USD | 1.11% |
| 2014 Q2 | -8.55 Million USD | 0.96% |
| 2013 Q2 | -7.94 Million USD | 33.22% |
| 2013 Q3 | -7.82 Million USD | 1.56% |
| 2013 Q4 | -8.73 Million USD | -11.57% |
| 2013 FY | - USD | 45.08% |
| 2013 Q1 | -11.9 Million USD | 9.59% |
| 2012 Q2 | -18.48 Million USD | 2.41% |
| 2012 Q3 | -15.83 Million USD | 14.36% |
| 2012 Q4 | -13.16 Million USD | 16.84% |
| 2012 FY | - USD | 20.16% |
| 2012 Q1 | -18.94 Million USD | -7.79% |
| 2011 Q3 | -19.82 Million USD | 8.45% |
| 2011 Q1 | -24.39 Million USD | -327.29% |
| 2011 Q4 | -17.57 Million USD | 11.35% |
| 2011 Q2 | -21.65 Million USD | 11.23% |
| 2011 FY | - USD | -99.77% |
| 2010 Q3 | -18.1 Million USD | -6.21% |
| 2010 Q1 | -16.53 Million USD | 10.18% |
| 2010 Q4 | 10.73 Million USD | 159.28% |
| 2010 Q2 | -17.04 Million USD | -3.1% |
| 2010 FY | - USD | 41.25% |
| 2009 Q4 | -18.4 Million USD | -6.01% |
| 2009 Q2 | -17.1 Million USD | -5.41% |
| 2009 Q1 | -16.22 Million USD | 25.57% |
| 2009 Q3 | -17.36 Million USD | -1.55% |
| 2009 FY | - USD | -8.23% |
| 2008 Q3 | -17.31 Million USD | -13.29% |
| 2008 Q2 | -15.28 Million USD | 2.38% |
| 2008 FY | - USD | 14.83% |
| 2008 Q1 | -15.65 Million USD | -6.83% |
| 2008 Q4 | -21.79 Million USD | -25.93% |
| 2007 Q2 | -16.3 Million USD | 47.23% |
| 2007 Q4 | -14.65 Million USD | -0.91% |
| 2007 Q3 | -14.52 Million USD | 10.93% |
| 2007 FY | - USD | -43.56% |
| 2007 Q1 | -30.88 Million USD | -143.07% |
| 2006 FY | - USD | -33.53% |
| 2006 Q4 | -12.7 Million USD | -7.66% |
| 2006 Q3 | -11.8 Million USD | -6.41% |
| 2006 Q2 | -11.09 Million USD | -9.12% |
| 2006 Q1 | -10.16 Million USD | -4.77% |
| 2005 FY | - USD | -408.32% |
| 2005 Q4 | -9.7 Million USD | 20.06% |
| 2005 Q3 | -12.13 Million USD | -329.06% |
| 2005 Q2 | -2.82 Million USD | 69.57% |
| 2005 Q1 | -9.29 Million USD | -4.27% |
| 2004 FY | - USD | 151.11% |
| 2004 Q2 | -7.34 Million USD | -118.38% |
| 2004 Q4 | -8.91 Million USD | 0.55% |
| 2004 Q1 | 39.98 Million USD | 657.68% |
| 2004 Q3 | -8.96 Million USD | -22.01% |
| 2003 Q1 | -7.01 Million USD | -71.67% |
| 2003 FY | - USD | 18.74% |
| 2003 Q4 | -7.17 Million USD | -69.7% |
| 2003 Q3 | -4.22 Million USD | 38.49% |
| 2003 Q2 | -7.64 Million USD | 5.14% |
| 2002 Q2 | -9.48 Million USD | 16.09% |
| 2002 Q3 | -7.01 Million USD | 23.05% |
| 2002 Q4 | -4.21 Million USD | 39.89% |
| 2002 FY | - USD | -66.02% |
| 2002 Q1 | -10.86 Million USD | -126.54% |
| 2001 Q2 | -7.04 Million USD | 16.96% |
| 2001 Q3 | -10.31 Million USD | -46.32% |
| 2001 FY | - USD | 13.08% |
| 2001 Q1 | -8.48 Million USD | -985.55% |
| 2001 Q4 | -4.79 Million USD | 53.49% |
| 2000 Q1 | -8.58 Million USD | -157.65% |
| 2000 Q4 | -782 Thousand USD | 86.95% |
| 2000 Q3 | -5.99 Million USD | 3.34% |
| 2000 Q2 | -6.19 Million USD | 7.48% |
| 2000 FY | - USD | -442.21% |
| 1999 FY | - USD | 146.32% |
| 1999 Q2 | -4.25 Million USD | 554.76% |
| 1999 Q3 | -6.5 Million USD | -134.03% |
| 1999 Q4 | -2.6 Million USD | 60.0% |
| 1999 Q1 | -3.5 Million USD | -16.67% |
| 1998 FY | - USD | -22.52% |
| 1998 Q2 | -3.1 Million USD | -66.67% |
| 1998 Q3 | -3 Million USD | 10.0% |
| 1998 Q4 | -2.9 Million USD | 0.0% |
| 1998 Q1 | -1.9 Million USD | -50.0% |
| 1997 Q3 | -1.9 Million USD | 7.69% |
| 1997 FY | - USD | 13.28% |
| 1997 Q2 | -2 Million USD | 43.48% |
| 1997 Q1 | -4.3 Million USD | -15.0% |
| 1997 Q4 | -1.1 Million USD | 33.33% |
| 1996 Q1 | -2.4 Million USD | 0.0% |
| 1996 Q4 | -3.3 Million USD | -21.21% |
| 1996 Q2 | -2.5 Million USD | -3.7% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | -2.8 Million USD | -17.86% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 9.043% |
| Alkermes plc | 495.04 Million USD | 135.306% |
| Agenus Inc. | -145.92 Million USD | -19.776% |
| Aptorum Group Limited | -9.59 Million USD | -1720.836% |
| Ardelyx, Inc. | -55.35 Million USD | -215.753% |
| Dyadic International, Inc. | -8.22 Million USD | -2023.785% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -59962.543% |
| Lantern Pharma Inc. | -15.78 Million USD | -1007.148% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -777.755% |
| Novavax, Inc. | -487.39 Million USD | 64.139% |
| Janux Therapeutics, Inc. | -71.02 Million USD | -146.089% |
| Pyxis Oncology, Inc. | -78.49 Million USD | -122.672% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -872.445% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -1653.431% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -204.626% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 54.001% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -624.879% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 33140.076% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | -11.188% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | -133.619% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -767.017% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -636.389% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -658.01% |
| C4 Therapeutics, Inc. | -122.1 Million USD | -43.143% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 32.319% |
| AlloVir, Inc. | -190.14 Million USD | 8.08% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 0.507% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -497.382% |
| Bicycle Therapeutics plc | -183.4 Million USD | 4.699% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | -5.659% |
| ChromaDex Corporation | -3.89 Million USD | -4388.495% |
| Chimerix, Inc. | -92.97 Million USD | -87.99% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -293.328% |
| Caribou Biosciences, Inc. | -112.53 Million USD | -55.315% |
| CRISPR Therapeutics AG | -202.7 Million USD | 13.773% |
| Precision BioSciences, Inc. | -32.04 Million USD | -445.478% |
| Fate Therapeutics, Inc. | -172.22 Million USD | -1.482% |
| Fortress Biotech, Inc. | -133.64 Million USD | -30.783% |
| Fortress Biotech, Inc. | -133.64 Million USD | -30.783% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | -125.983% |
| ImmuCell Corporation | -2.5 Million USD | -6879.897% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | -34.014% |
| Immix Biopharma, Inc. | -16.13 Million USD | -983.204% |
| Incyte Corporation | 919.42 Million USD | 119.01% |
| Innoviva, Inc. | 248.96 Million USD | 170.205% |
| IO Biotech, Inc. | -91.22 Million USD | -91.588% |
| Jaguar Health, Inc. | -33.13 Million USD | -427.548% |
| Keros Therapeutics, Inc. | -152.17 Million USD | -14.854% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 271.815% |
| ContextLogic Inc. | -324 Million USD | 46.055% |
| MiMedx Group, Inc. | 40.51 Million USD | 531.379% |
| MEI Pharma, Inc. | 26.38 Million USD | 762.555% |
| NextCure, Inc. | -59.03 Million USD | -196.045% |
| Onconetix, Inc. | -36.7 Million USD | -376.158% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 7920.224% |
| Opthea Limited | -200.01 Million USD | 12.617% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -6252.06% |
| Vaxcyte, Inc. | -464.88 Million USD | 62.403% |
| PDS Biotechnology Corporation | -40.08 Million USD | -336.029% |
| Precigen, Inc. | -89.22 Million USD | -95.887% |
| Pharming Group N.V. | 9.87 Million USD | 1869.586% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | -9.892% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -667.867% |
| PureTech Health plc | -11.62 Million USD | -1403.242% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -929.28% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 25.146% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -624.879% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -99.918% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -503.466% |
| Acelyrin, Inc. | -381.52 Million USD | 54.189% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -1356388.104% |
| Summit Therapeutics Inc. | 1 Million USD | 17560.739% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -423.519% |
| Senti Biosciences, Inc. | -61.33 Million USD | -184.958% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | -55.633% |
| Elevation Oncology, Inc. | -41.46 Million USD | -321.497% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -465.564% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -2757.528% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -54349.221% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -438.57% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -1981.729% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -197.299% |
| Seer, Inc. | -97.88 Million USD | -78.559% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -181.014% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -167.394% |
| ESSA Pharma Inc. | -26.45 Million USD | -560.669% |
| GlycoMimetics, Inc. | -39.12 Million USD | -346.762% |
| GT Biopharma, Inc. | 5.97 Million USD | 3023.265% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 15.439% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -2444.875% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 301.334% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -207.964% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -241.244% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -1667.813% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 67.629% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -2438.96% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -272.972% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 26.135% |
| Aptose Biosciences Inc. | -52.26 Million USD | -234.396% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | -62.221% |
| Soligenix, Inc. | -7.85 Million USD | -2125.714% |
| Century Therapeutics, Inc. | -121.2 Million USD | -44.2% |
| Kura Oncology, Inc. | -164.95 Million USD | -5.957% |
| TScan Therapeutics, Inc. | -80.09 Million USD | -118.21% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -1632.917% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -18149.44% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -3956.208% |
| Autolus Therapeutics plc | -156.77 Million USD | -11.489% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -106.459% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | -153.304% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -776.803% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 7.656% |
| GRI Bio, Inc. | -10.89 Million USD | -1503.799% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -3770.528% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | -42.672% |
| IGM Biosciences, Inc. | -253.35 Million USD | 31.014% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -68.396% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -358.346% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -1040.063% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -1010.203% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -207.471% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | -63.191% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 34.292% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 9.878% |
| Verastem, Inc. | -83.16 Million USD | -110.16% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -245.61% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | -10.462% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | -53.198% |
| Histogen Inc. | -10.5 Million USD | -1564.115% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -1123.989% |
| Surrozen, Inc. | -41.13 Million USD | -324.94% |
| Organovo Holdings, Inc. | -14.8 Million USD | -1080.481% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 5450115.591% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -197.688% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -240.746% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -711.468% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -1996.209% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | -5.248% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -254.826% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -623.256% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -1060.953% |
| Apollomics, Inc. | -171.74 Million USD | -1.767% |
| Amarin Corporation plc | -50.9 Million USD | -243.373% |
| Mesoblast Limited | -61.33 Million USD | -184.981% |
| Turnstone Biologics Corp. | -56.23 Million USD | -210.812% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | -22.054% |
| Synaptogenix, Inc. | -8.3 Million USD | -2003.904% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -1039.462% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -177.225% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -3547.777% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 40838.021% |
| Exelixis, Inc. | 196.6 Million USD | 188.901% |
| Better Therapeutics, Inc. | -38.26 Million USD | -356.803% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | -23.6% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 64.706% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1381.749% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 70800.116% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -492.361% |
| Gritstone bio, Inc. | -126.86 Million USD | -37.772% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -168.957% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -4269.609% |
| Avid Bioservices, Inc. | -11.48 Million USD | -1422.359% |
| Insmed Incorporated | -654.73 Million USD | 73.305% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -7669.059% |
| MediWound Ltd. | -4.89 Million USD | -3472.083% |
| OmniAb, Inc. | -49.73 Million USD | -251.455% |
| Alector, Inc. | -142.89 Million USD | -22.318% |
| Seres Therapeutics, Inc. | -85.43 Million USD | -104.581% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -235.165% |
| Zai Lab Limited | -366.57 Million USD | 52.32% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 39.862% |
| Aura Biosciences, Inc. | -83.69 Million USD | -108.83% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 22.405% |
| Immunic, Inc. | -99.11 Million USD | -76.348% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | -32.742% |
| Veracyte, Inc. | -49.4 Million USD | -253.745% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -2374.288% |
| FibroGen, Inc. | -261.4 Million USD | 33.137% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1468.818% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -2396.412% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -833.821% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 112.059% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -587.523% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 538.16% |
| TG Therapeutics, Inc. | 26.1 Million USD | 769.663% |
| Galecto, Inc. | -37.51 Million USD | -365.849% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -356.767% |
| Fortrea Holdings Inc. | 167.3 Million USD | 204.472% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | -30.162% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -517.364% |
| XBiotech Inc. | -35.76 Million USD | -388.682% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -168.957% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -167.865% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | -67.328% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -580.827% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -327.685% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 66.157% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -211.994% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -311726.729% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | -50.24% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -688.388% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 25.645% |
| NexImmune, Inc. | -28.16 Million USD | -520.509% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -3063.161% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -1382.174% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 103.755% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -588.335% |
| Scopus BioPharma Inc. | -11.71 Million USD | -1392.186% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | -38.886% |
| Ainos, Inc. | -8.77 Million USD | -1892.249% |
| Pluri Inc. | -20.22 Million USD | -764.188% |
| Prothena Corporation plc | -190.1 Million USD | 8.062% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | -36.338% |
| Celularity Inc. | -183.94 Million USD | 4.982% |
| Rallybio Corporation | -72.37 Million USD | -141.502% |
| Cue Biopharma, Inc. | -46.05 Million USD | -279.532% |
| MeiraGTx Holdings plc | -57.05 Million USD | -206.356% |
| Omeros Corporation | -163.61 Million USD | -6.828% |
| Humacyte, Inc. | -96.45 Million USD | -81.2% |
| Immunocore Holdings plc | -59.64 Million USD | -193.017% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -802.24% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -617.349% |
| Blueprint Medicines Corporation | -474.61 Million USD | 63.174% |
| CalciMedica, Inc. | -34.18 Million USD | -411.223% |
| Cabaletta Bio, Inc. | -73.23 Million USD | -138.662% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | -39.272% |
| Scholar Rock Holding Corporation | -168.45 Million USD | -3.758% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 30.749% |
| Pulmatrix, Inc. | -12.64 Million USD | -1282.113% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -430.189% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | -97.567% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 65.48% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | -72.684% |
| Cytokinetics, Incorporated | -456.68 Million USD | 61.728% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -423.723% |
| Nutriband Inc. | -5.12 Million USD | -3312.527% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -303.915% |
| Vor Biopharma Inc. | -114.37 Million USD | -52.82% |
| Roivant Sciences Ltd. | -996.51 Million USD | 82.461% |
| Evogene Ltd. | -23.2 Million USD | -653.241% |
| ProKidney Corp. | -147.66 Million USD | -18.361% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -170.833% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -114025.46% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 69.091% |
| CorMedix Inc. | -48.88 Million USD | -257.522% |
| BioLineRx Ltd. | -57.06 Million USD | -206.307% |
| Tango Therapeutics, Inc. | -111.75 Million USD | -56.393% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -86425.743% |
| Atai Life Sciences N.V. | -36.31 Million USD | -381.347% |
| Renovaro Biosciences Inc. | -79.51 Million USD | -119.805% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | -114.95% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 36.559% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -468.582% |
| MediciNova, Inc. | -9.87 Million USD | -1669.054% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | -38.781% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -11322.16% |
| GeoVax Labs, Inc. | -26.66 Million USD | -555.381% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 22.316% |
| Biomea Fusion, Inc. | -124.62 Million USD | -40.252% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 47.09% |
| Mereo BioPharma Group plc | -26.05 Million USD | -570.794% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 8.173% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 23.989% |
| Absci Corporation | -95.45 Million USD | -83.1% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -482.122% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | -63.168% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 25.139% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -664.743% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 15.904% |
| Allakos Inc. | -189.91 Million USD | 7.968% |
| Imunon, Inc. | -19.87 Million USD | -779.261% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | -61.101% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 261.351% |
| BioAtla, Inc. | -122.24 Million USD | -42.981% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1381.749% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -1008.952% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 41.796% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -321.7% |
| XOMA Corporation | -39.36 Million USD | -344.037% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | -76.096% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -48.561% |
| aTyr Pharma, Inc. | -52.17 Million USD | -234.973% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | -108.533% |
| Akero Therapeutics, Inc. | -148.63 Million USD | -17.595% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 25.487% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -1180.173% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -2073.284% |
| Akari Therapeutics, Plc | -16.8 Million USD | -940.245% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 92721.326% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 138.673% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -2635.831% |
| UroGen Pharma Ltd. | -63.83 Million USD | -173.82% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -157.354% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -2306.467% |
| Orgenesis Inc. | -60.71 Million USD | -187.859% |
| Entera Bio Ltd. | -8.8 Million USD | -1885.257% |
| GH Research PLC | -41.15 Million USD | -324.713% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -584.909% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | -112.545% |
| Xencor, Inc. | -125.87 Million USD | -38.855% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -12152.12% |
| Replimune Group, Inc. | -230.19 Million USD | 24.073% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -767.077% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -1497.35% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -2635.831% |
| Portage Biotech Inc. | -18.19 Million USD | -860.393% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -11322.16% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | -67.121% |
| OncoCyte Corporation | -23.12 Million USD | -655.879% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -1446.694% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -1425.569% |
| Purple Biotech Ltd. | -22.22 Million USD | -686.421% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -2626.708% |
| scPharmaceuticals Inc. | -46.06 Million USD | -279.458% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -881.388% |
| HilleVax, Inc. | -132.46 Million USD | -31.945% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -1543.769% |
| Tharimmune, Inc. | -9.3 Million USD | -1778.853% |
| Genprex, Inc. | -31.06 Million USD | -462.714% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 6.796% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -457.447% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -22777.225% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 115923.305% |
| OKYO Pharma Limited | -15.74 Thousand USD | -1109918.056% |
| Savara Inc. | -59.13 Million USD | -195.574% |
| Curis, Inc. | -45.13 Million USD | -287.208% |
| Daré Bioscience, Inc. | -30.7 Million USD | -469.294% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -1050.552% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -2339.386% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -553.782% |
| BeiGene, Ltd. | -1.12 Billion USD | 84.458% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -972.203% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 59.408% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | -93.471% |
| Erasca, Inc. | -121.31 Million USD | -44.079% |
| bluebird bio, Inc. | -167.16 Million USD | -4.559% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -3785.118% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 156.33% |
| DBV Technologies S.A. | -85.98 Million USD | -103.277% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -3785.118% |
| Moderna, Inc. | -3.28 Billion USD | 94.676% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -310.2% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -2994.582% |
| Molecular Templates, Inc. | 1.43 Million USD | 12322.517% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -192.024% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 46.426% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | -27.495% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -269.003% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | -25.712% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 15.097% |
| MacroGenics, Inc. | 2.01 Million USD | 8765.444% |
| RenovoRx, Inc. | -11.39 Million USD | -1434.522% |
| Adicet Bio, Inc. | -136.53 Million USD | -28.013% |
| Prime Medicine, Inc. | -193.75 Million USD | 9.794% |
| Aditxt, Inc. | -25.45 Million USD | -586.551% |
| Adagene Inc. | -14.95 Million USD | -1069.049% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2290.967% |
| Quantum-Si incorporated | -91.8 Million USD | -90.386% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 124.534% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 238.217% |
| SciSparc Ltd. | -5.28 Million USD | -3209.012% |
| Vericel Corporation | 2.86 Million USD | 6202.723% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -183479.111% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -705.765% |
| Generation Bio Co. | -133.3 Million USD | -31.119% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -110.505% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | -103.181% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 23.15% |
| Invivyd, Inc. | -196.61 Million USD | 11.104% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 53.286% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -1784.483% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 743.669% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -1599.387% |
| 2seventy bio, Inc. | -206.41 Million USD | 15.326% |
| ADMA Biologics, Inc. | 5.12 Million USD | 3513.711% |
| Clene Inc. | -43.24 Million USD | -304.204% |
| Capricor Therapeutics, Inc. | -23 Million USD | -659.625% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -260.546% |
| GeoVax Labs, Inc. | -26.66 Million USD | -555.381% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 41.655% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -375.865% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 841.45% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 3659.53% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -438.089% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | -10.339% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 74.458% |
| Evaxion Biotech A/S | -21.4 Million USD | -716.624% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -163.166% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 19.703% |
| Trevena, Inc. | -35.28 Million USD | -395.302% |
| Surrozen, Inc. | -41.13 Million USD | -324.94% |
| Tyra Biosciences, Inc. | -79.59 Million USD | -119.597% |
| Cingulate Inc. | -22.95 Million USD | -661.51% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -2242.608% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -368.798% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -2024.655% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | -70.909% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -157.688% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -199.428% |
| Clearmind Medicine Inc. | -8.71 Million USD | -1906.529% |
| Kronos Bio, Inc. | -121.83 Million USD | -43.464% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | -135.105% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -7059.048% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -73.348% |
| Statera Biopharma, Inc. | 38.93 Million USD | 548.908% |
| ImmunityBio, Inc. | -436.18 Million USD | 59.929% |
| Korro Bio, Inc. | -80.9 Million USD | -116.036% |
| Kineta, Inc. | -15.71 Million USD | -1012.269% |
| BioVie Inc. | -31.95 Million USD | -447.045% |
| Codexis, Inc. | -49.28 Million USD | -254.65% |
| Celularity Inc. | -183.94 Million USD | 4.982% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 21.095% |
| Celcuity Inc. | -58.3 Million USD | -199.746% |
| Virax Biolabs Group Limited | -6.6 Million USD | -2544.548% |
| Cibus, Inc. | -314.58 Million USD | 44.44% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -418.134% |
| IN8bio, Inc. | -28.5 Million USD | -513.184% |
| Kodiak Sciences Inc. | -259.02 Million USD | 32.523% |
| Annexon, Inc. | -141.57 Million USD | -23.455% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | -55.225% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -172.263% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -525.226% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 24.011% |
| Eyenovia, Inc. | -24.1 Million USD | -625.055% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 490.278% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -53845.062% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | -136.819% |
| Arcellx, Inc. | -64.14 Million USD | -172.48% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -288.284% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | -41.551% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -465.967% |
| Moolec Science SA | -52.07 Million USD | -235.632% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -238.685% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -332.447% |
| Royalty Pharma plc | 1.88 Billion USD | 109.261% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | -46.147% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1774.488% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -742.698% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | -5.24% |
| Humacyte, Inc. | -96.45 Million USD | -81.2% |
| Structure Therapeutics Inc. | -102.45 Million USD | -70.587% |
| 89bio, Inc. | -134.46 Million USD | -29.985% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | -121.594% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 4413.475% |
| Genelux Corporation | -24.16 Million USD | -623.286% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -417.107% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | -6.924% |
| Notable Labs, Ltd. | -14.4 Million USD | -1113.764% |
| Liquidia Corporation | -70.05 Million USD | -149.507% |
| Mustang Bio, Inc. | -48.06 Million USD | -263.652% |
| Immunovant, Inc. | -269.97 Million USD | 35.261% |
| Quantum-Si incorporated | -91.8 Million USD | -90.386% |
| Arbutus Biopharma Corporation | -70.98 Million USD | -146.22% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -805.231% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -71.335% |
| Acasti Pharma Inc. | -11.3 Million USD | -1446.606% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -685.423% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -1040.063% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 16.973% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -3992.926% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -1000.642% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -507.388% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -372.001% |
| PepGen Inc. | -83.58 Million USD | -109.114% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -492.401% |
| United Therapeutics Corporation | 1.38 Billion USD | 112.603% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -663.34% |
| Solid Biosciences Inc. | -93.43 Million USD | -87.065% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -3562.86% |
| Immuneering Corporation | -58.06 Million USD | -201.033% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 5450115.591% |
| Silo Pharma, Inc. | -3.62 Million USD | -4719.958% |
| Belite Bio, Inc | -31.52 Million USD | -454.353% |
| XOMA Corporation | -39.36 Million USD | -344.037% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -159.14% |
| Bionomics Limited | -9.83 Million USD | -1676.782% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -108.111% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -405.063% |
| uniQure N.V. | -253.1 Million USD | 30.944% |
| Cassava Sciences, Inc. | -95.68 Million USD | -82.66% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2290.967% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -34.963% |
| Forte Biosciences, Inc. | -32.47 Million USD | -438.172% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -2071.077% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -519.377% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -53845.062% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1468.818% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -999.189% |
| Altimmune, Inc. | -87.93 Million USD | -98.763% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -89.817% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -405.063% |
| Compugen Ltd. | -12.51 Million USD | -1296.469% |
| Peak Bio, Inc. | -1356.23 USD | -12887242.117% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -259.649% |
| Benitec Biopharma Inc. | -22.49 Million USD | -677.154% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 27.866% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -512.346% |
| Zura Bio Limited | -60.56 Million USD | -188.595% |
| PolyPid Ltd. | -20.26 Million USD | -762.567% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -1019.465% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -512.346% |
| Instil Bio, Inc. | -146.12 Million USD | -19.614% |
| argenx SE | -216.02 Million USD | 19.091% |
| Immunome, Inc. | -28.27 Million USD | -518.238% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -260.576% |
| Verona Pharma plc | -52.46 Million USD | -233.124% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | -84.424% |
| Shattuck Labs, Inc. | -87.61 Million USD | -99.489% |
| CervoMed Inc. | -2.17 Million USD | -7947.52% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | -42.978% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -1276.995% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -262.814% |
| Moolec Science SA | -52.07 Million USD | -235.632% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -919.733% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | -34.045% |
| AnaptysBio, Inc. | -143.16 Million USD | -22.085% |
| Design Therapeutics, Inc. | -66.32 Million USD | -163.524% |
| Leap Therapeutics, Inc. | -80.98 Million USD | -115.815% |
| NeurAxis, Inc. | -6.66 Million USD | -2522.584% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -362.999% |
| Lumos Pharma, Inc. | -36.57 Million USD | -377.938% |
| Achilles Therapeutics plc | -70.44 Million USD | -148.122% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | -84.424% |
| 180 Life Sciences Corp. | -22.13 Million USD | -689.653% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 3098.363% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -7059.048% |
| Nutriband Inc. | -5.12 Million USD | -3312.527% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | -59.258% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -215.309% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -245.761% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -167.754% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -223.013% |
| Palisade Bio, Inc. | -12.28 Million USD | -1323.19% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -285.186% |
| Beam Therapeutics Inc. | -156.47 Million USD | -11.701% |
| Neurogene Inc. | -52.28 Million USD | -234.281% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | -28.055% |
| AEON Biopharma, Inc. | -48.36 Million USD | -261.411% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | -87.901% |
| Sesen Bio, Inc. | -50.84 Million USD | -243.788% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | -113.326% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -1315.236% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 59.109% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | -66.147% |
| Athira Pharma, Inc. | -116.7 Million USD | -49.767% |
| Vaccinex, Inc. | -19.74 Million USD | -785.062% |
| HCW Biologics Inc. | -23.57 Million USD | -641.354% |
| XOMA Corporation | -39.36 Million USD | -344.037% |
| Nektar Therapeutics | -243.1 Million USD | 28.105% |
| Arvinas, Inc. | -394.8 Million USD | 55.729% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 92721.326% |
| Merus N.V. | -149.2 Million USD | -17.141% |
| Omega Therapeutics, Inc. | -93.49 Million USD | -86.953% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -459.123% |
| Rezolute, Inc. | -68.42 Million USD | -155.443% |
| Clene Inc. | -43.24 Million USD | -304.204% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -1033.315% |
| BeyondSpring Inc. | -21.54 Million USD | -711.43% |
| Synlogic, Inc. | -55.16 Million USD | -216.858% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -1346.512% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -1542.379% |
| Peak Bio, Inc. | -1356.23 USD | -12887242.117% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -438.371% |
| Krystal Biotech, Inc. | 17.9 Million USD | 1076.218% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | -47.591% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 48.796% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -3694.303% |
| MannKind Corporation | 15.12 Million USD | 1255.278% |
| Ikena Oncology, Inc. | -74.39 Million USD | -134.932% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -1287.93% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 959.851% |
| Gossamer Bio, Inc. | -172.15 Million USD | -1.528% |
| CohBar, Inc. | -12.06 Million USD | -1348.579% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -585.178% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -482.122% |
| Legend Biotech Corporation | -477.87 Million USD | 63.425% |
| Mural Oncology plc | -192.72 Million USD | 9.308% |
| Biora Therapeutics, Inc. | -114.05 Million USD | -53.245% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -982.559% |
| Disc Medicine, Inc. | -91.02 Million USD | -92.015% |
| Champions Oncology, Inc. | -5.05 Million USD | -3358.29% |
| REGENXBIO Inc. | -239.46 Million USD | 27.011% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -1530.705% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -213.477% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -350.838% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | -54.94% |
| Vaxart, Inc. | -74.72 Million USD | -133.907% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -396.423% |
| Cellectis S.A. | -98.09 Million USD | -78.176% |
| Longeveron Inc. | -20.06 Million USD | -771.296% |
| Repare Therapeutics Inc. | -114.27 Million USD | -52.951% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 60.204% |
| Inozyme Pharma, Inc. | -74.81 Million USD | -133.628% |
| Revolution Medicines, Inc. | -430.58 Million USD | 59.408% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -2679.17% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -467.677% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -134.324% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 3664.797% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -1493.999% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 103.795% |
| Denali Therapeutics Inc. | -179.97 Million USD | 2.884% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -183479.111% |
| Veru Inc. | -89.97 Million USD | -94.255% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -550.279% |
| Cingulate Inc. | -22.95 Million USD | -661.51% |
| Passage Bio, Inc. | -98.34 Million USD | -77.731% |
| Context Therapeutics Inc. | -25.06 Million USD | -597.438% |
| Exicure, Inc. | -15.53 Million USD | -1024.796% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 15.181% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -372.69% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -2831.307% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | -3.75% |
| Nuvalent, Inc. | -149.49 Million USD | -16.917% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -2049.202% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | -103.486% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -479.17% |
| OmniAb, Inc. | -49.73 Million USD | -251.455% |
| Anew Medical, Inc. | -1.3 Million USD | -13336.087% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -1313.636% |
| Lipocine Inc. | -16.32 Million USD | -970.793% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -162.16% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | -135.229% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -358.346% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -347.998% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -687.91% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 67.934% |
| Ocugen, Inc. | -64.82 Million USD | -169.613% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | -88.811% |
| Q32 Bio Inc. | -86.5 Million USD | -102.055% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -932.563% |
| Alumis Inc. Common Stock | -156.89 Million USD | -11.404% |
| Equillium, Inc. | -12.13 Million USD | -1339.957% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -198.916% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -2111.493% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -826.686% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -274.33% |
| Evelo Biosciences, Inc. | -106.34 Million USD | -64.354% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -877.168% |
| Dominari Holdings Inc. | -22.44 Million USD | -678.886% |
| Edesa Biotech, Inc. | -8.19 Million USD | -2034.053% |
| vTv Therapeutics Inc. | -25.41 Million USD | -587.793% |
| Bio-Techne Corporation | 326.66 Million USD | 153.505% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 54.586% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 180.772% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | -33.311% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -366.945% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | -15.672% |
| Nkarta, Inc. | -120.48 Million USD | -45.07% |
| BioCardia, Inc. | -11.56 Million USD | -1411.955% |
| Iterum Therapeutics plc | -34.58 Million USD | -405.442% |